# US 2011/0212091 A1 · Materials and methods for inhibiting cancer cell invasion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0212091 A1
- Document ID: US20110212091A1
- Status: Published application
- Kind: A1
- Application number: 13/061,058
- Filed: 2009-09-02
- Published: 2011-09-01
- Earliest claimed: 2008-09-03
- Assignees: Licentia Ltd.
- Inventors: Kari Alitalo; Kaisa Lehti; Jorma Keski-Oja; Annamari Alitalo
- Web page: https://patentgrep.com/patent/US20110212091A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 38/179: {for growth factors; for growth regulators}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides an isolated antibody or antibody fragment thereof that binds an extracellular epitope of a fibroblast growth factor receptor-4 (FGFR4) that is expressed by mammalian cells and inhibits cancer cell invasion. Optionally, the antibody or fragment thereof binds an epitope of FGFR4 that is bound by monoclonal antibody F90-10C5, or comprises complementarity determining regions identical to those of monoclonal antibody F90-10C5. Also provided are methods of using the antibody or fragment thereof to modulate invasion, ingrowth, or metastasis of cancer cells and treat cancer in a subject. The invention additionally provides a method of identifying an antibody or antibody fragment that inhibits invasiveness.

## Claims

### Claim 96

An isolated monoclonal antibody, or fragment thereof, or a polypeptide that comprises a fragment of the antibody;
wherein the antibody, fragment, or polypeptide binds an extracellular epitope of a fibroblast growth factor receptor-4 (FGFR4) that is expressed by mammalian cells; and
wherein the antibody, fragment, or polypeptide exhibits at least one activity selected from the group consisting of:
inhibiting cancer cell invasion in a mammal;
inhibiting fibroblast growth factor 2 (FGF2)-induced phosphorylation of FGFR4 R388 in mammalian cells that express FGFR4 R388;
enhancing FGF2-induced degradation of fibroblast growth factor receptor-1 (FGFR1) in mammalian cells that co-express FGFR4 R388 and FGFR1; and
inhibiting complex formation between FGFR4 and membrane type-1 metalloproteinase (MT1-MMP) in mammalian cells that co-express FGFR4 R388 and MT1-MMP.

### Claim 97 (depends on 96)

The isolated monoclonal antibody, antibody fragment, or polypeptide according to claim 96 that binds an extracellular epitope of an FGFR4 that comprises the amino acid sequence of SEQ ID NO: 1 or 2.

### Claim 98 (depends on 97)

The isolated monoclonal antibody, antibody fragment, or polypeptide of claim 97, wherein the antibody, fragment, or polypeptide binds at least one FGFR4 peptide that consists of an amino acid sequence selected from the group consisting of SEQ ID NOS: 5-9.

### Claim 99 (depends on 97)

The isolated monoclonal antibody, antibody fragment, or polypeptide of claim 97, wherein the antibody, fragment, or polypeptide binds an FGFR4 extracellular epitope that comprises amino acid residues 79-81 of SEQ ID NO: 1 or 2.

### Claim 100 (depends on 97)

The isolated monoclonal antibody, antibody fragment, or polypeptide of claim 97, wherein the antibody is monoclonal antibody F90-10C5 (DSM ACC2967).

### Claim 101 (depends on 97)

The isolated monoclonal antibody, antibody fragment, or polypeptide of claim 97 that is a humanized antibody, a human antibody, a chimeric antibody, or comprises a fragment of the human, humanized, or chimeric antibody that binds an extracellular epitope of FGFR4 that is expressed by mammalian cells.

### Claim 102 (depends on 101)

The isolated monoclonal antibody, antibody fragment, or polypeptide of claim 101, further comprising an anti-neoplastic or cytotoxic agent conjugated or attached thereto.

### Claim 103 (depends on 101)

A composition comprising the isolated monoclonal antibody, antibody fragment, or polypeptide of claim 101 (“the first monoclonal antibody or fragment thereof”) and a physiologically acceptable carrier.

### Claim 104 (depends on 103)

The composition of claim 103, further comprising a second monoclonal antibody or fragment thereof, or a polypeptide that comprises a fragment thereof (“second monoclonal antibody or fragment thereof”), wherein the second monoclonal antibody or fragment thereof binds a second extracellular epitope of the FGFR4 that is different than the epitope recognized by the first monoclonal antibody or fragment thereof.

### Claim 105 (depends on 103)

The composition of claims 103, further comprising a membrane type-1 metalloproteinase (MT1-MMP) inhibitor.

### Claim 106

An isolated monoclonal antibody, or fragment thereof, or a polypeptide that comprises a fragment of the antibody; wherein the antibody, fragment, or polypeptide binds an FGFR4 extracellular epitope that comprises amino acid residues 79-81 of SEQ ID NO: 1 or 2.

### Claim 107 (depends on 96)

An isolated cell that produces the antibody, antibody fragment, or polypeptide of claim 96.

### Claim 108 (depends on 107)

The isolated cell of claim 107 that is from a hybridoma cell line deposited under Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ) Deposit Accession Number DSM ACC2967.

### Claim 109

An isolated monoclonal antibody, antibody fragment, or polypeptide that comprises a fragment of the antibody, wherein the antibody, fragment, or polypeptide comprises all complementarity determining regions (CDR) of monoclonal antibody F85-6C5 (DSM ACC2966) or monoclonal antibody F90-3B6 (DSM ACC2965), or comprises the variable regions of monoclonal antibody F85-6C5 or F90-3B6, and wherein the antibody, antibody fragment, or polypeptide binds an extracellular epitope of FGFR4 that is expressed by mammalian cells.

### Claim 110 (depends on 109)

An isolated cell that produces the antibody, antibody fragment, or polypeptide of claim 109.

### Claim 111 (depends on 110)

The isolated cell of claim 110 that is from a hybridoma cell line selected from: hybridoma cell line deposited under DSMZ Deposit Accession Number DSM ACC2966; and hybridoma cell line deposited under DSMZ Deposit Accession Number DSM ACC2965.

### Claim 112 (depends on 96)

A method of treatment comprising: administering to a mammalian subject with cancer the antibody, antibody fragment, or polypeptide of claim 96.

### Claim 113 (depends on 112)

The method of claim 112, wherein the antibody, antibody fragment, or polypeptide is administered in an amount effective to inhibit invasion, ingrowth, or metastasis of cancer cells in the mammalian subject.

### Claim 114 (depends on 112)

The method of claim 112, wherein the mammalian subject is human.

### Claim 115 (depends on 114)

The method of claim 114, wherein the cancer is selected from breast cancer, bladder cancer, melanoma, prostate cancer, mesothelioma, lung cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, colorectal cancer, and pancreatic cancer.

### Claim 116 (depends on 114)

The method according to claim 114, wherein the cancer is a cancer determined to have at least one FGFR4 allele that encodes FGFR4 R388.

### Claim 117 (depends on 114)

The method of claim 114, further comprising a step of determining the presence or absence of an FGFR4 allele that encodes FGFR4 R388 in the cancer, wherein the treatment is administered if the cancer has at least one FGFR4 allele that encodes FGFR4 R388.

### Claim 118 (depends on 114)

The method according to claim 114, further comprising administering to the subject one or more of the following:
a second monoclonal antibody or fragment thereof, wherein the second monoclonal antibody or fragment thereof binds a second extracellular epitope of FGFR4 that is different than the epitope recognized by the first monoclonal antibody or fragment thereof;
a composition comprising a membrane type-1 metalloproteinase (MT1-MMP) inhibitor; and
a standard of care anti-cancer therapy.

### Claim 119 (depends on 118)

The method according to claim 118, comprising administering the second monoclonal antibody or fragment thereof, wherein the second monoclonal antibody or fragment inhibits ligand-independent FGFR4 phosphorylation.

### Claim 120

A composition comprising an adjuvant and at least one of:
an isolated antigenic peptide consisting of 5-25 amino acids of the amino acid sequence encoding FGFR4, wherein the peptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 5-9 or a fragment thereof;
an isolated polynucleotide encoding the antigenic peptide; and
a vector comprising the polynucleotide.

### Claim 121

A method of selecting an antibody or antibody fragment, wherein the method comprises:
(a) obtaining one or more antibodies or antibody fragments that bind FGFR4;
(b) screening the antibodies or antibody fragments in a tumor cell invasiveness assay; and
(c) selecting an antibody that inhibits invasiveness in the assay by at least 50%.
